VC
Vivo Capital Portfolio holdings
AUM
$977M
This Quarter Return
+13.76%
1 Year Return
+209.68%
3 Year Return
+1,480.07%
5 Year Return
+2,591.98%
10 Year Return
–
AUM
$2.23B
AUM Growth
+$2.23B
(-3.6%)
Cap. Flow
-$165M
Cap. Flow
% of AUM
-7.42%
Top 10 Holdings %
Top 10 Hldgs %
65.91%
Holding
64
New
5
Increased
3
Reduced
16
Closed
4
Top Buys
| 1 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$41.9M |
| 2 |
Viridian Therapeutics
VRDN
|
$21.4M |
| 3 |
Sera Prognostics
SERA
|
$20.6M |
| 4 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$13.4M |
| 5 |
Harmony Biosciences
HRMY
|
$13.4M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$122M |
| 2 |
Celldex Therapeutics
CLDX
|
$26.2M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$26M |
| 4 |
Legend Biotech
LEGN
|
$23.7M |
| 5 |
Novavax
NVAX
|
$18.7M |
Sector Composition
| 1 | Healthcare | 85.61% |
| 2 | Financials | 7.21% |
| 3 | Materials | 7.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Aclaris Therapeutics
ACRS
$209M
| $16.9M | 0.76% | 940,754 -433,525 | -32% | -$7.8M |
|
|
MREO
27
Mereo BioPharma
MREO
$272M
| $16.7M | 0.75% | 6,907,189 +2,686,251 | +64% | +$6.5M |
|
|
VRNA
28
Verona Pharma
VRNA
$9.16B
| $15.1M | 0.68% | 2,749,918 -298,589 | -10% | -$1.64M |
|
29
Nkarta
NKTX
$151M
| $14.2M | 0.64% | 512,225 | – | – |
|
|
DICE
30
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $13.4M | 0.6% | +410,000 | New | +$13.4M |
|
|
GRCL
31
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $13.3M | 0.6% | 961,359 -366,898 | -28% | -$5.09M |
|
32
Curis
CRIS
$20.9M
| $12.2M | 0.55% | 1,553,500 | – | – |
|
33
Cogent Biosciences
COGT
$1.69B
| $12M | 0.54% | +1,420,941 | New | +$12M |
|
|
KDNY
34
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $11.1M | 0.5% | 872,151 | – | – |
|
35
Aurinia Pharmaceuticals
AUPH
$1.58B
| $11.1M | 0.5% | 500,732 | – | – |
|
|
36
Crinetics Pharmaceuticals
CRNX
$2.92B
| $10.9M | 0.49% | 517,280 -1,235,066 | -70% | -$26M |
|
37
Arcutis Biotherapeutics
ARQT
$1.86B
| $10.4M | 0.47% | 433,585 | – | – |
|
38
Kura Oncology
KURA
$686M
| $9.84M | 0.44% | 525,262 | – | – |
|
39
Merus
MRUS
$4.98B
| $9.72M | 0.44% | 442,000 | – | – |
|
40
Dyne Therapeutics
DYN
$1.92B
| $9.38M | 0.42% | 577,642 | – | – |
|
41
Codexis
CDXS
$246M
| $9.03M | 0.41% | 388,144 | – | – |
|
42
Arrowhead Research
ARWR
$3.05B
| $8.58M | 0.39% | 137,411 | – | – |
|
43
ESSA Pharma
EPIX
$11.4M
| $8.45M | 0.38% | 1,056,067 -495,613 | -32% | -$3.97M |
|
44
Zymeworks
ZYME
$1.12B
| $8.31M | 0.37% | 286,064 | – | – |
|
45
Design Therapeutics
DSGN
$315M
| $7.8M | 0.35% | 530,991 | – | – |
|
46
Q32 Bio
QTTB
$20.9M
| $6.71M | 0.3% | 853,143 | – | – |
|
|
VALN
47
Valneva
VALN
$753M
| $6.28M | 0.28% | 200,000 -200,000 | -50% | -$6.28M |
|
48
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.12M | 0.27% | 320,000 | – | – |
|
|
STSA
49
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $5.74M | 0.26% | 1,232,394 | – | – |
|
50
Passage Bio
PASG
$22.7M
| $5.37M | 0.24% | 539,263 -106,738 | -17% | -$1.06M |
|